Raymond James set a $10.00 target price on IMV (NYSE:IMV) in a research report sent to investors on Thursday morning, BayStreet.CA reports. The firm currently has an outperform rating on the stock.
Several other equities analysts have also recently weighed in on the company. Zacks Investment Research cut IMV from a buy rating to a hold rating in a research report on Saturday, October 26th. Wells Fargo & Co began coverage on IMV in a research report on Monday, October 28th. They issued a market perform rating for the company. Finally, HC Wainwright set a $11.50 price target on IMV and gave the company a buy rating in a research report on Monday, September 30th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $8.94.
Shares of NYSE IMV traded down $0.30 during mid-day trading on Thursday, hitting $2.58. The company had a trading volume of 8,241 shares, compared to its average volume of 19,864. IMV has a 1 year low of $2.25 and a 1 year high of $7.07. The stock’s 50-day moving average price is $2.74 and its 200-day moving average price is $3.15.
Institutional investors have recently bought and sold shares of the stock. Hartford Financial Management Inc. lifted its stake in shares of IMV by 9.6% in the 3rd quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock valued at $94,000 after acquiring an additional 3,348 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of IMV by 3.6% during the 2nd quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after acquiring an additional 3,453 shares during the period. Citadel Advisors LLC purchased a new position in shares of IMV during the 2nd quarter worth approximately $37,000. Bank of Montreal Can grew its stake in shares of IMV by 17.5% in the 2nd quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after buying an additional 13,228 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of IMV by 260.5% in the 2nd quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after buying an additional 65,300 shares during the last quarter.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Featured Story: Cost of Capital
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.